Ask about this productRelated genes to: SLC39A6 antibody
- Gene:
- SLC39A6 NIH gene
- Name:
- solute carrier family 39 member 6
- Previous symbol:
- -
- Synonyms:
- LIV-1
- Chromosome:
- 18q12.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-10-08
- Date modifiied:
- 2016-02-17
Related products to: SLC39A6 antibody
Related articles to: SLC39A6 antibody
- The zinc transporter SLC39A6, a member of the ZIP (Zrt-Irt-like protein) family, mediates zinc influx from the extracellular milieu into the cytosol and is indispensable for the function of numerous enzymes, transcription factors and signaling molecules. Previous studies have shown that SLC39A6 expression is associated with prognosis in esophageal squamous cell carcinoma and cervical cancer, indicating its potential impact on patient survival and tumor immunity. But a comprehensive pan-cancer analysis of SLC39A6 is still lacking. This study aimed to systematically delineate the oncogenic and prognostic relevance of SLC39A6 across multiple cancer types, to unravel its interplay with immune-infiltration patterns in the tumor micro-environment, and to preliminarily identify SLC39A6-associated therapeutic vulnerabilities. - Source: PubMed
Publication date: 2026/05/18
Hongmin LiYufei WangYuwei WangDongqi YuanMengjie LiYudong SuPeng ChenJinghua Zhang - While many Antibody Drug Conjugates (ADCs) are investigated in solid tumors, their target expression and heterogeneity is poorly documented in metastatic breast cancer. Here, we perform RNA sequencing to investigate expression of 72 ADC targets in 909 samples from 30 female patients from our post-mortem tissue donation program UPTIDER (NCT04531696). We report that the highest median expression in metastases is seen for FN1, MUC1, LAMP1, HER3 and SLC39A6. TROP2 and HER2 have the 9 and 27 highest expression. We observe reduced expression in metastases as compared to primary untreated tumors for 15 targets but observe only limited differences in expression between metastases of different subtypes. We show that TROP2, VTCN1, NECTIN4, HER2 and HER3 are interesting targets as they have higher mRNA expression in tumor as compared to normal tissues. This is confirmed at the protein level by explorative immunohistochemistry. Correlations between targets can help guide design of bispecific ADCs. Taken together, the results of this study can help inform the design and prioritization of drugs for the treatment of patients with metastatic breast cancer. - Source: PubMed
Publication date: 2025/12/26
Borremans KristienPabba AnirudhZels GitteMahdami AmenaCarette CamilleMaetens MarionVan Baelen KarenVan Cauwenberge JosephineNguyen Ha LinhIzci HavaLeduc SophiaHatse SigridNysen MaditaBoeckx BramVanderheyden EvyBrussel Thomas VanDerouane FrançoisePunie KevinVan Den Bogaert WouterVermeulen PeterBiganzoli EliaLambrechts DietherNeven PatrickWildiers HansFloris GiuseppeRichard FrançoisDesmedt Christine - Solute carrier (SLC) transporters have been linked to type 2 diabetes (T2D) and play a crucial role in cellular metabolism. Growth and metabolism depend on ornithine decarboxylase 1 (ODC1), a crucial regulator of polyamine production, especially in the pancreas. This study examines the interaction between ODC1 and SLC gene expressions under glucotoxicity conditions, which simulate hyperglycemia. In silico analysis of human pancreatic β-islet tissue datasets from T2D patients identified differentially expressed SLC genes. In vitro studies were conducted using HEK293T cells and COS-7 cell lines. Overexpression and knockdown of ODC1 in HEK293T cells revealed ODC1's influence on the mRNA expression profiles of SLC. In vitro overexpression with and without high glucose also revealed ODC1's influence on SLC genes. Specifically, ODC1 modulated the expression of SLC11A2, SLC30A1, SLC39A6, and other SLCs, including SLC17A6, SLC25A12, SLC26A2, SLC35A5, SLC38A2, SLC9A6, SLC6A8, and SLC20A1. Glucotoxicity mostly suppressed SLC gene expression; however, ODC1 overexpression partially reversed this effect for certain SLCs. This work highlights an unrecognized regulatory network involving ODC1 and SLCs, suggesting a potential role for polyamine pathway modulation in controlling transport dynamics. These findings suggest a novel regulatory network where ODC1 influences SLC gene expression, impacting metabolic pathways and nutrient transport. This study provides preliminary evidence that ODC1 may be a potential regulator of SLC transporters, offering new insights into the metabolic dysregulation of T2D and potential therapeutic targets. - Source: PubMed
Publication date: 2025/06/24
Kaur ManpreetDahiya NehaSingh Varsha - Canine oral squamous cell carcinoma (COSCC) is the second most common oral tumor in dogs and the most relevant for comparative human trials as a spontaneous large animal model of disease. Historical genomic work has focused primarily on bulk sequencing. The present study describes the complete transcriptomic landscape of COSCC with spatial distinction between the surface tumor, deep invasive tumor, peritumoral dysplastic epithelium, and tumor microenvironment compared to matched normal oral samples. Each region demonstrated distinct molecular signatures. Genes related to epithelial growth factor (EGFR) and epithelial-mesenchymal transformation (EMT) were upregulated in both peritumoral dysplasia and surface cancer. Additionally, the KRAS gene set, KRT17, and SSP1 were enriched in cancer. We identified five genes that represent dysplastic lesion with high potential for malignant transformation (FZD4, GAS1, HACD2, NOG, and SLC39A6). Also, three genes, SFRP4, FZD1, and IL34 represented a specific signature of the invasive portion of the COSCC that should be explored for prognostic value as a biomarker of malignancy. Lastly, we verified the immunomodulatory tumor microenvironment detecting an increase in macrophages and an abundance of IL-10 secretion. The other predominant leukocytes were T-cells, with CD4+ T-cells being the most prevalent. CD4+ T cells expressed transcripts for both stimulatory (Inducible T-cell Co-Stimulator (ICOS) and inhibitory molecules (CTLA4). The observed high CTLA4 suggests that this inhibitory signal may be preventing a robust antitumor immune response. Taken together, this study identified multiple targets to be explored for biomarkers of malignancy, prediction of tumor behavior, and potential targets for development of novel therapies. - Source: PubMed
Publication date: 2025/06/17
Goldschmidt StephanieTepper Clifford GGoon JackSoltero-Rivera MariaRebhun RobertBirkeland Andrew CWang Xiao-JingDavis Ryan RLiu Stephenie YRivas IrisMurphy BrianVapniarsky Natalia - Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, necessitating the development of novel therapeutic strategies. We explore the expression characteristics of SLC39A6 in CRC by combining multiple cohorts and multi-omics. The therapeutic effect and potential mechanism of BRY812 on CRC were explored through in vitro experiments. Our research results show that the expression of SLC39A6 in CRC tissues is higher than that in normal tissues, and it is closely related to tumor pathways, making it a good therapeutic target. BRY812 has an inhibitory effect on the growth, migration and stemness of CRC cells, and may exert its killing effect by downregulating the AKT pathway. This study has identified SLC39A6 as a potential therapeutic target in CRC. BRY812 is expected to become a highly promising therapeutic drug, bringing new hope to patients with CRC. - Source: PubMed
Publication date: 2025/05/25
Liu XianglinLiu WenqiangWu YutingWang YichuanJiang QingliangLi YangyangLi HengyuHao Liqiang